KRYS Corporate Deck - JPM 2026 vFinal.pdf

1、 Copyright 2026 Krystal Biotech,Inc.All rights reserved.Genetic Medicines for High Unmet Medical Needs JPM 2026Krystal|2Forward Looking Statements and DisclosuresForward Looking Statements This presentation and our discussion contain forward-looking statements that involve substantial risks and unce

2、rtainties.Any statements about future expectations,plans,and prospects for Krystal Biotech,Inc.(together with its subsidiaries,the“Company”),including but not limited to,statements about our global VYJUVEK launch;selected preliminary 2025 unaudited results;our 2030 vision and the market potential of

3、 the product candidates that could be launched over the next four years;the development and commercial potential of our product candidates,including our expectations for our product pipeline,including clinical trial plans,enrollment in clinical trials,and the timing of initiating clinical trials,dos

4、ing patients,data read-outs,and regulatory submissions;our platform technology designation and potential benefits;and other statements about our business,operations,and financial results,constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

5、Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,including:uncertainties associated with regulatory reviews and the content and timing of regulatory authorities decisions;uncertainties in the initiation and conduct

6、of clinical trials and availability and timing of data from clinical trials;whether results of early clinical trials will be indicative of the results of ongoing or future trials;the availability or commercial potential of product candidates;and such other important factors as are set forth in the C